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9.25/100,000 in women in 2012 (2). Irrespective of 
recent trends, Croatia had the sixth highest mortal-
ity rate in Europe for both men (2.95/100,000) and 
women (1.91/100,000) in 2012 (2,3). MM caused 
an estimated loss of 4297.04 Disability Adjusted 
Life Years (DALYs) (4), and accounted for 0.51% of 
all Years of Life Lost (YLLs) in Croatia in 2013 (4). 
 
INTRODUCTION
Mortality and five-year survival for malignant 
melanoma of the skin (MM) in Croatia are poor com-
pared with those in most European countries, but 
recent mortality trends indicate some progress when 
compared with other countries in Central and South-
Eastern Europe (1-3). Age-standardized incidence 
rates (W) in Croatia were 8.75/100,000 in men, and 
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ABSTRACT Mortality rates and five-year relative survival for malignant mel-
anoma (MM) of the skin in Croatia are poor compared with most European 
countries. Epidemiological data recorded at the National Cancer Registry 
(CNCR) are used for informing various decision-makers and researchers, as 
well as for comparisons with other countries. We analyzed CNCR data on 
MM skin and morphology for 2000-2007 and 2008-2014 and compared 
them with European 2000-2007 data. We further stratified skin site analyses 
in Croatia by sex, different age groups, and sources of reports. We found 52% 
of case with “non-specified sites” in Croatia in 2000-2007; however, that pro-
portion decreased to 36% in 2008-2014, with 29% of registered MM cases 
occurring on the trunk, 22% on the limbs, and 13% on the head and neck. 
The proportion of “non-specified sites” cases in reports originating from 
university hospitals decreased by 25% and by 9.2% in those from general 
hospitals. The proportion of “not otherwise specified” among histologically 
verified cases decreased from 96% in 2000-2007 to 84% in 2008-2014. Our 
results reveal a substantial proportion of inadequately reported cases, in 
particular when compared to data at the European level, where in 2000-
2007 only 7.7% of cases were from “non-specified sites” and 19% were of 
non-specified morphology. Irrespective of recent progress, the proportion 
of unspecified cases still hampers insight into site distribution by subgroups. 
A further increase in the overall completeness of MM data within CNCR is 
needed to enable research-informed improvement of melanoma control in 
the country. Our findings call for engagement of all stakeholders in optimi-
zation of the national melanoma registration processes and using models 
such as RegisTree© to facilitate these initiatives.
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However, the relevance of MM societal burden is 
greater in the younger population, since it accounted 
for an estimated 1.16% of all YLL in the age group 15-
49 (4). There is neither an official strategy nor action 
plan for dealing with the melanoma burden at the 
national level, but the epidemiological data recorded 
at the National Cancer Registry (CNCR) are used for 
informing various decision-makers and researchers, 
as well as for comparisons with other countries.
Results of a EUROpe against cancer: Optimisation of 
the Use of Registries for Scientific Excellence in research 
(EUROCOURSE) project have shown that, at the Euro-
pean level, cancer registry data were most actively used 
in several overlapping cancer research areas, including 
Public Health, Quality of Care, Survivorship, and Prog-
nosis (5). According to the results of the latest EURO-
pean Cancer REgistry Based Study on Survival and Care 
of Cancer Patients (EUROCARE) study, five-year relative 
survival for MM diagnosed between 2000 and 2007 
was 83.2% at European level, but 70.6% in Croatia, with 
only Bulgaria, Latvia, Lithuania, and Poland having low-
er survival (1). The EUROCARE-5 study also compared 
quality of data on MM, along with proportions of MM 
cases of different localizations and morphological sub-
types among different European regions (1). MM risk 
factors differ by skin site and histological type, suggest-
ing different etiologic pathways of melanoma develop-
ment by skin site (6). Proportions of MM of different lo-
calizations and morphological subtypes varied among 
different European regions, and so did relative survival 
by MM skin site and morphological subtype (1). 
The aim of this study was to compare CNCR data 
on MM skin sites and morphology with the European 
level results of the EUROCARE-5 study, both within the 
EUROCARE-5 study period and in recent years, further 
disaggregate them by sex and different age groups, as 
well as sources of reports. We discuss the implications 
of the findings on melanoma surveillance and control 
in Croatia at the national and regional level, as well 
as the need for continuous and improved monitoring 
given the recent major treatment developments.
PATIENTS AND METHODS
CNCR was founded in 1959, as one of the oldest 
national registries in Europe, has contributed data to 
  Table 1 Skin melanoma case reports according to skin-sites and morphology: EUROCARE-5 results for Europe 2000-2007   
  compared with Croatian data for 2000-2007 and for 2008-2014.
Europe 2000-20072 Croatia 2000-2007 Croatia 2008-2014
Skin-site1 ICD-10 Code
Head and neck C43.0-C43.4 N 37,245 512 503
% 15.4 13.6 12.9
Trunk C43.5 N 78,675 750 1118
% 32.6 20.0 28.6
Limbs C43.6 – C43.7 N 106,939 526 873
% 44.3 14.0 22.4
Not specified sites C43.8 - C43.9 N 18,626 1966 1411
% 7.7 52.4 36.1
All cases C43.0 – C43.9 N 241,485 3754 3905
Morphology1 Morphology Code
Nodular melanoma 8721 N 14,721 76 210
% 14.9 2.1 5.6
Lentigo maligna 8742 N 5932 0 8
% 6.0 0.0 0.2
Superficial spreading 8743 N 51,783 27 288
% 52.3 0.7 7.7
Other specified sites3 - N 7571 44 96
% 7.6 1.2 2.6
Not otherwise specified 8720 N 19,061 3505 3136
% 19.2 96.0 84.1
All cases N 99,068 36524 37304
ICD=International Classification of Diseases
1 Aggregated in line with EUROCARE-5 report on melanoma (1). 
2 EUROCARE-5 data, based on contributions from 86 cancer registries for skin-sites and from 51/86 cancer registries ‘with 
adequate information on morphology’ (arbitrarily defined as <30% not otherwise specified (NOS), code 8720 (1).
3 Includes codes 8722-3, 8730, 8740-1, 8744-6, 8761, 8770-4 and 8780.
4 Excludes autopsy  and death certificate–only cases, n=102 (2000-2007), n=175 (2008-2014). 
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Cancer Incidence in Five Continents, volumes VII-X (7), 
and has recently participated in international cancer 
survival studies, EUROCARE-5 and CONCORD-2 (8,9). 
We obtained incidence data on MM (ICD-10 C43*) for 
the 2000-2014 period from CNCR and stratified them 
in two time periods: 2000-2007 and 2008-2014. CNCR 
collects data from various sources, both from the pub-
lic and private sector, coded according to ICD-10 clas-
sification for topography and ICD-O-3 classification 
for morphology. This includes notifications received 
from health professionals working at hospital wards, 
outpatient clinics, and general practitioners as well as 
official cause of death statistics. The registry also re-
ceives pathological reports from hospital pathology 
departments. The notifications are first sent to the lo-
cal County Public Health institute, whose staff, after 
the first phase of quality control, forwards the data 
to CNCR. The diagnosis of melanoma is accepted by 
the cancer registry only if the basis of diagnosis was 
histological or cytological confirmation that provides 
morphological diagnosis. 
We compared our results with the results for Eu-
rope 2000-2007 from the EUROCARE-5 study, which 
was based on data contributions from 86 European 
cancer registries (1). Based on the C43 code exten-
sion, we stratified the data in four skin site groups as 
the ones used in the EUROCARE-5 report on mela-
noma, namely “head and neck” (C43.0-C43.4), “trunk” 
(C43.5), “limbs” (C43.6-C43.7), and “non-specified 
sites” (C43.8-C43.9). We calculated the proportions 
in each group in the total number of reported cases. 
We also stratified the cases by morphological types, 
using morphological codes, namely “nodular mela-
noma” (8721), “lentigo maligna” (8742), “superficial 
spreading melanoma” (8743), “other specified sites” 
(including codes 8722-3, 8730, 8740-1, 8744-6, 8761, 
8770-4, and 8780), and “not otherwise specified” (NOS, 
8720). We further stratified the data on skin sites by 
sex, age (≤59 years and 60+ years), and by both sex 
and age (≤59 years and 60+ years) and calculated the 
proportions of each skin site in the total number of 
cases in each of the eight subgroups. Additionally, we 
stratified the sources of the reports in three groups: 
“university hospitals” (including university hospital 
centers and university hospitals), general hospitals, 
and “other sources”, and then analyzed proportions 
of “non-specified sites” reports (C43.8-C43.9) for both 
time periods.
RESULTS
We found 3754 reported melanoma cases in 
Croatia in the 2000-2007 period, and 3905 in the 
2008-2014 period (Table 1). The proportion of cases 
reported among “non-specified sites” decreased from 
52% to 36% between the two periods. The propor-
tion of melanomas localized on the trunk and limbs 
increased, whereas the proportion of head and neck 
melanomas decreased between the two periods in 
Croatia, as shown in Table 1. Compared with Croatian 
data, data collected in the EUROCARE-5 study had 
lower proportion of “non-specified sites” cases (7.7%), 
higher proportions of limb melanomas and trunk 
Figure 1. Reported cases of skin melanoma and proportions according to skin-sites in Croatia, 2000-2007, for all ages, 
both sexes and for different subgroups. 
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Figure 2. Reported cases of skin melanoma and proportions according to skin-sites in Croatia, 2008-2014, for all ages, both 
sexes and for different subgroups. 
melanomas, and a similar proportion of head and 
neck melanomas reported during 2000-2007 (Table 
1). Most cases among histologically verified MM re-
ported in Croatia were coded as NOS, with a decrease 
from 96 % to 84% between the two periods (Table 1). 
The number of reported cases recorded in 2000-
2007 varied by different subgroups, as did propor-
tions of head and neck, limb, and trunk melanomas, 
but the proportion of cases from “non-specified sites” 
was around 50% across all subgroups (Figure 1). 
The proportion of “non-specified” sites was not as 
consistent across different subgroups during 2008-
2014 (Figure 2). 
Absolute numbers of cases and the proportion of 
cases reported from university hospitals decreased 
from 2466 cases, i.e. 65.7% of all reported cases in 
2000-2007, to 2066 cases, i.e. 52.9% of all reported 
cases in 2008-2014 (Table 2). The absolute numbers 
of cases and the proportions of cases reported from 
general hospitals and other sources increased be-
tween the two periods (Table 2). The proportion of 
“non-specified sites” cases in reports originating from 
university hospitals decreased by 25% and by 9.2% in 
those from general hospitals, but it remained stable 
in those originating from other sources (Table 2). 
   Table 2. Cases of skin melanoma reported to Croatian National Cancer Registry in the periods 2000-2007 and      
   2008-2014, by report source. 
Source
Period Skin melanoma case reports 








2000-2007 All cases, C43.0 – C43.9 N 2466 717 571 3754
Not specified sites, C43.8 - C43.9 N 1322 357 286 1966
% 53.6 49.7 50.1 52.4
2008-2014 All cases, C43.0 – C43.9 N 2066 1023 816 3905
Not specified sites, C43.8 - C43.9 N 588 414 409 1411
% 28.5 40.5 50.1 36.1
ICD=International Classification of Diseases; C43.8= Malignant melanoma of overlapping sites of skin; C43.9= Malignant 
melanoma of skin, unspecified. 
1 Includes university hospital centers and university hospitals.
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DISCUSSION
The proportion of “non-specified sites” MM among 
the reported cases in Croatia is decreasing, as well as 
the ratio of cases with non-specified morphology. Ir-
respective of recent progress in these data quality in-
dicators, which are most prominent in cases originat-
ing from university hospitals, our results reveal a sub-
stantial proportion of inadequately reported cases, in 
particular when compared with European-level data. 
This lack of high-quality data limits insight into na-
tionwide site-distribution and morphological types, 
in particular by different age and sex subgroups. 
A scheme has been developed to facilitate bet-
ter use of cancer registry data in different cancer 
research areas, in which cancer registries have been 
visualized as trees (“Cancer Registration Tree” – Reg-
isTree©) (10). RegisTree© represents “transmission and 
refinery capacity (through their trunks and height 
– information) by a combination of fluids (through 
roots – data), energy from sunlight (through leaves 
– inspiration, ideas), and regular production of nuts 
and fruits (information)” (10). Our results illustrate 
some areas for improvement of the Croatian “Mela-
noma Registration Tree”, including the input from 
“roots”, i.e. completeness of data on skin sites, as well 
as the “fruits”, i.e. countrywide insight into site-distri-
bution by subgroups, but also how improvement of 
input coming from “roots” has led to improvement of 
“fruits” over time. Differences in proportions of differ-
ent localization of MM cases among European regions 
point to the fact that, although data from other coun-
tries or regions can be useful in guiding public health 
research and prevention efforts in individual coun-
tries, local epidemiological data is needed for fully 
informed decisions on customization at the national 
level (1). Reliable Croatian national-level data on MM 
skin sites and morphology could add focus and ad-
ditional value in designing prevention messages for 
public and healthcare professionals and contribute 
to more effective communication (11). Furthermore, 
Croatia has joined the EUROMELANOMA campaign 
in 2008 and has several other preventive activities 
underway, but the effect of these efforts can only be 
monitored and evaluated through adequate mela-
noma surveillance at the national level (11). Similarly, 
other melanoma research areas where CNCR data 
can be used have specific features in the Croatian set-
ting (5). Along with lower survival and higher mortal-
ity rates, Croatia has comparatively lower resources 
available not only for prevention, but also for treat-
ment of advanced melanoma, and so poor decisions 
on allocation of resources have a greater opportunity 
cost as compared with wealthier Western European 
countries (3,11,12). Inadequate resource allocation 
leads to missed opportunities for earlier diagnoses 
and timely surgical treatment for a greater propor-
tio of MM patients in Croatia, and thus increases the 
pool of those with advanced disease in need of costly 
treatments. Considering the low resource capacity in 
Croatia, this probably translates to limited access to 
novel therapeutic possibilities for the patients who 
could receive the greatest benefit. 
Awareness of the importance of the quality of 
reported mortality and incidence data, and the com-
plementary value of population-based and institu-
tion-based registries in achieving horizontal synergy 
in melanoma research seems to be increasing among 
clinicians in Croatia and Central Europe (13-15). Po-
tential input in the CNCR (“roots”) comes from each 
phase of the journey of the patient with melanoma, 
from detection to cure or death (10). This includes 
general practitioners, dermatologists, surgeons, on-
cologists, pathologists, nuclear medicine specialists, 
and palliative care providers, who are commonly 
involved in different areas of melanoma research as 
well (10). To ensure that the future reporting does 
not overburden their busy schedules, but that the 
output of CNCR (“fruits”) still meets their needs, all 
stakeholders should be engaged in reaching con-
sensus on national optimization of the registration 
processes (5). For example, the increasing proportio 
of cases reported to CNCR from non-hospital sources 
(Table 2) suggests an increasing importance of CNCR 
melanoma data at the national level in the context of 
Breslow thickness. Data on Breslow thickness are cur-
rently occasionally (i.e. not routinely) reported from 
clinical registries in individual institutions, mostly uni-
versity hospitals, as they are usually active in research 
and publish such data thanks to their scientific efforts 
(14,15). Considering our findings presented in Table 
2, one could hypothesize that thinner melanomas 
get excised in non-university hospital or non-hospital 
settings, and thus nationwide melanoma thickness 
could be overestimated if based on data from hospital 
registries, in particular university hospital registries. 
Collection of Breslow thickness data in CNCR could 
thus be considered for gaining a more accurate and 
reliable perspective. This would also enable explora-
tion of trends of Breslow thickness like in other coun-
tries (16). Furthermore, Crocetti et al. indicate the pos-
sibility of overdiagnosis as a limitation of melanoma 
survival analyses within the EUROCARE-5 study (1). 
One could speculate that comparatively lower mela-
noma survival in Croatia may in part be explained 
by a lesser extent of overdiagnosis than in Northern 
and Western European countries. However, exploring 
and answering this and other questions relevant for 
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different stakeholders in Croatia, such as the dynamics 
of melanoma societal burden, is currently not possible 
like it is in other countries with available comprehen-
sive national data on Breslow thickness (17-19). 
CONCLUSION
Irrespective of recent progress, most prominent 
in reports originating from university hospitals, in 
comparison with EUROCARE-5 results the proportion 
of unspecified cases in CNCR is still comparatively 
high and hampers countrywide insight into site-dis-
tribution by subgroups. Due to practical reasons, the 
second period we analyzed (2008-2014) is one year 
shorter than the first one (2000-2007), which should 
be taken into consideration when interpreting our 
results. A further increase in overall completeness of 
MM data within CNCR is needed to enable research-
informed improvement of melanoma control in 
Croatia. Our results call for future engagement of all 
stakeholders in the optimization of national melano-
ma registration processes and creating a well rooted 
melanoma “registry tree”, enabling it to fully blossom, 
with future fruits meeting everyone’s needs. 
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